In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, filgrastim, a granulocyte colony stimulating factor, was added to the complementary list of the EML and EMLc for use in the following indications: - primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy; - secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy; - to facilitate administration of dose dense chemotherapy regimens. The relevant extract from TRS994 regarding the Expert Committee's consideration of G-CSF is attached.